Illumina, Inc. ILMN
270.00
(3.90)
(1.42%)
as of 25 Sep
- Market cap
- $41.3B
- P/E
- 50.4×
Follow ILMN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Illumina, Inc. (ILMN) P/E ratio
As of 25 September 2026, Illumina, Inc. (ILMN) trades at a P/E ratio of 50.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 110× (February 2021); the current reading is higher than 62% of that period. That is above the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 23.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 72.7× | (9.50%) |
| FY2020 | 80.3× | 69.54% |
| FY2019 | 47.4× | (8.72%) |
| FY2018 | 51.9× | 19.11% |
| FY2017 | 43.6× | 7.63% |
| FY2016 | 40.5× | (30.82%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 32.5× | 45.81% |
| Mar 2026 | 22.3× | (6.87%) |
| Dec 2025 | 23.9× | 12.65% |
| Sep 2025 | 21.2× | 76.36% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 110×
Ten-year median
44.8×
Current reading's percentile
62
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.8× |
| IQV IQVIA Holdings Inc. compare | 33.3× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| A Agilent Technologies, Inc. compare | 33.9× |
| IDXX IDEXX Laboratories, Inc. compare | 36.2× |
| ILMN Illumina, Inc. | 50.4× |
| WAT Waters Corporation compare | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on ILMN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement